Context:
One of the clients has launched a new oral medication for Type 2 Diabetes. The HEOR team wants to compare its real-world effectiveness against existing therapies using claims and EHR data.

Resolution:
Our team identified patients with Type 2 Diabetes initiating therapy which was compared to HbA1c reduction at 6 months between new drug vs. standard therapy and then assessed adherence (Proportion of Days Covered, PDC). Finally, they summarize safety outcomes (hypoglycaemia events).

Result:
The outcome analysis resulted as HbA1c reduction wherein paired t-test or mixed model was finalised. The Adherence showed PDC ≥ 80% threshold and in terms of frequency of hypoglycaemia ICD codes was analysed under safety.